Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ImmuPro
- Development stage
- Preclinical
- Lead developer
- Cytobiologics
- Modality
- Recombinant Proteins and Enzymes
01
Overview
ImmuPro is a plasma-derived immunoglobulin (IVIG) therapy developed by Cytobiologics, the plasma derivatives manufacturing arm of Promea. It is designed as a replacement therapy to provide pooled antibodies for patients with primary or secondary immunodeficiencies, as well as for its immunomodulatory effects in treating various autoimmune and neurological disorders. As a plasma-derived product, it contains a broad spectrum of IgG antibodies harvested from healthy donors, providing passive immunity and helping to regulate the immune system in inflammatory conditions. The product is part of Cytobiologics' portfolio of plasma-derived protein replacement therapies.
- Brand names
- ImmuPro
Beyond the preview
Go deeper on ImmuPro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuPro.